Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.32 |
| ▸ | ENPP3 | O14638 | 7/20 | 0.31 |
| ▸ | ENPP1 | P22413 | 5/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.31 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.31 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.31 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7044189 | 0.93 | ENPP3 (0.33) | ENPP3ENPP1ENPP2 | |
| SCHEMBL6017806 | 0.90 | ENPP3 (0.32) | ENPP3ENPP1ENPP2 | |
| SCHEMBL6017766 | 0.89 | ENPP3 (0.31) | ENPP3ENPP1ENPP2 | |
| SCHEMBL6018120 | 0.85 | ENPP3 (0.30) | ENPP3ENPP1ENPP2 | |
| SCHEMBL5036606 | 0.85 | ENPP3 (0.33) | ENPP3ENPP1ENPP2 | |
| SCHEMBL6017660 | 0.84 | ENPP3 (0.33) | ENPP3ENPP1ENPP2 | |
| SCHEMBL6018066 | 0.84 | ENPP3 (0.31) | ENPP3ENPP1ENPP2 | |
| SCHEMBL5037986 | 0.82 | DRD2 (0.34) | — | |
| SCHEMBL5037949 | 0.82 | CNR2 (0.33) | ENPP3ENPP1ENPP2 | |
| SCHEMBL6017897 | 0.82 | ENPP3 (0.33) | ENPP3ENPP1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041668-B2 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | disclosed |
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | CDKL3, CCNL2, CDKL1 | KCNH3 1637/4885ENPP3 2927/4885ENPP1 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.